Program
obicetrapib
Also written as “TA-8995”, “Obicetrapib” and “Obicetrapib 10 mg”.
Its studies are mostly in Dyslipidemias · Hypercholesterolemia · Alzheimer Disease · Hyperlipidemias · Atherosclerosis, led by 3 companies.
Drug pageTA-8995: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| NewAmsterdam Pharma | 197 open or running | phase 3since Nov 18, 2021 | Feb 9, 2021 | Nov 2026phase 2 · NCT06496243 |
| Xentionits history only | 60 open or running | phase 2since Oct 21, 2013 | Oct 21, 2013 | none ahead |
| Tanabe Pharmaits history only | 20 open or running | phase 1since Jun 4, 2013 | Jun 4, 2013 | none ahead |
Also a collaborator on its studies: Pharma Medica Research and Novum.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of NewAmsterdam Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 5 earlier studies, Feb 9, 2021 to Nov 23, 2021.
- Jun 9, 2016Named obicetrapibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, TA-8995
- Feb 23, 2022Phase 2 study in DyslipidemiasNCT05266586 · 119 enrolled · United States
- Jun 13, 2022Phase 2 study in DyslipidemiasNCT05421078 · 102 enrolled · Japan
- Jun 15, 2022Phase 3 study in DyslipidemiasNCT05425745 · 354 enrolled · United States, Canada, Czechia and more
- Jul 25, 2023Phase 1 study in Lipid MetabolismNCT05972278 · 22 enrolled · United States
- Aug 15, 2023Phase 3 study in DyslipidemiasNCT06005597 · 407 enrolled · United States
- Aug 29, 2023Phase 1 study in Hepatic ImpairmentNCT06048302 · 18 enrolled · United States
- Oct 3, 2023Phase 1 study in Healthy VolunteersNCT06081166 · 74 enrolled · Canada
- Feb 1, 2024Phase 1 study in Healthy VolunteersNCT06250205 · 30 enrolled · United States
- Feb 28, 2024Phase 3 study in HyperlipidemiasNCT06305559 · 300 enrolled · United States
- Jul 3, 2024Phase 2 study in DyslipidemiasNCT06496243 · 69 planned · United States
- Aug 1, 2024Phase 1 study in Healthy VolunteersNCT06547359 · 94 enrolled · Canada
- May 13, 2025Phase 2 study in Antioxidant AbsorptionNCT06982508 · 100 planned · United States
- Oct 20, 2025Phase 3 study in HyperlipidemiasNCT07219602 · 300 enrolled · United States, Czechia, Netherlands and more
- Aug 12, 2026Phase 2 study in Alzheimer DiseaseNCT07794670 · 400 planned · United States
Ahead
- Nov 2026Primary completion: phase 2 study in DyslipidemiasNCT06496243
- Nov 2026Primary completion: phase 3 study in AtherosclerosisNCT05202509
- Nov 2027Primary completion: phase 3 study in HyperlipidemiasNCT06305559
- Mar 2028Primary completion: phase 3 study in HyperlipidemiasNCT07219602
TargetBeta
“Cholesteryl ester transfer protein inhibitor”ChEMBL 37, by rule
Studies
All 19 NewAmsterdam Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07794670Alzheimer Disease · United States | 2 | Recruiting | Sep 2028 | 400 |
| NCT07219602Hyperlipidemias · United States, Czechia, Netherlands and more | 3 | Active, not recruiting | Mar 2028 | 300 |
| NCT06982508Antioxidant Absorption · United States | 2 | Recruiting | Sep 2026 | 100 |
| NCT06547359Healthy Volunteers · Canada | 1 | Completed | Nov 12, 2024 | 94 |
| NCT06496243Dyslipidemias · United States | 2 | Recruiting | Nov 2026 | 69 |
| NCT06305559Hyperlipidemias · United States | 3 | Active, not recruiting | Nov 2027 | 300 |
| NCT06250205Healthy Volunteers · United States | 1 | Completed | Apr 25, 2024 | 30 |
| NCT06081166Healthy Volunteers · Canada | 1 | Completed | Dec 2, 2023 | 74 |
| NCT06048302Hepatic Impairment · United States | 1 | Completed | Mar 12, 2024 | 18 |
| NCT06005597Dyslipidemias · United States | 3 | Completed | Sep 25, 2024 | 407 |
| NCT05972278Lipid Metabolism · United States | 1 | Active, not recruiting | Sep 26, 2024 | 22 |
| NCT05425745Dyslipidemias · United States, Canada, Czechia and more | 3 | Completed | May 28, 2024 | 354 |
| NCT05421078Dyslipidemias · Japan | 2 | Completed | Mar 24, 2023 | 102 |
| NCT05266586Dyslipidemias · United States | 2 | Completed | Aug 12, 2022 | 119 |
| NCT05161715Alzheimer Disease · Netherlands | 2 | Completed | May 9, 2023 | 13 |
| NCT05202509Atherosclerosis · United States, Australia, Bulgaria and more | 3 | Active, not recruiting | Nov 2026 | 9,541 |
| NCT05142722Dyslipidemias · United States, China, Czechia and more | 3 | Completed | Sep 26, 2024 | 2,530 |
| NCT04770389Dyslipidemias · United States, Netherlands | 2 | Completed | May 7, 2021 | 112 |
| NCT04753606Dyslipidemias · United States | 2 | Completed | May 24, 2021 | 120 |
How it is read
Names in the registry
- “TA-8995”, 16 entries
- “Obicetrapib”, 11 entries
- “Obicetrapib 10 mg”, 2 entries
- “obicetrapib 10 mg + ezetimibe 10 mg FDC daily”, 2 entries
- “Obicetrapib 10mg”, 2 entries
Conditions, from the studies’ own filings
- Dyslipidemias, 10 studies
- Hypercholesterolemia, 4 studies
- Alzheimer Disease, 2 studies
- Hyperlipidemias, 2 studies
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.